MedTrace Logo

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

NCT02162550 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2018-06-14

No results posted yet for this study

Summary

Investigators will be determining whether a once weekly injectable medication Bydureon versus placebo is able to reduce the development of atherosclerosis.

Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies will provide novel information about the temporal relationship between Bydureon induced changes in risk factors, endothelial function and atherosclerosis progression.

Conditions

Interventions

DRUG

Bydureon

once weekly injection

DRUG

placebo

once weekly injection

Sponsors & Collaborators

  • Phoenix VA Health Care System

    lead FED

Principal Investigators

  • Peter D Reaven, MD · Carl T. Hayden Medical Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2019-04-30
Completion
2019-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162550 on ClinicalTrials.gov